



## PharmaMar begins trading on Spanish BME stock exchange

- PharmaMar trading following a merger with Zeltia

**Madrid, November 2, 2015.** PharmaMar (MSE:PHM) announced today that the Company started trading on the BME Spanish stock exchange after completing the reverse merger with Zeltia. The new PharmaMar shares began trading this morning. The exchange ratio between the shares of the two companies was 1:1, one PharmaMar share for each Zeltia share.

The PharmaMar reverse merger with Zeltia had been approved in the Annual Shareholders meeting of Grupo Zeltia in accordance with the proposal of the Board of Directors. As a result of this corporate transaction, Zeltia has been absorbed by PharmaMar, a biopharmaceutical Company focused on the research, development and commercialization of innovative marine-derived anticancer drugs.

After the reverse merger between Zeltia and PharmaMar, the rest of the subsidiary companies formerly owned by Zeltia will be fully owned by PharmaMar.

### **Information for shareholders and investors**

Upon admission to trading, all PharmaMar shares were assigned a single ISIN code: ES0169501030. The basic particulars of PharmaMar are as follows:

Company name: Pharma Mar, S.A.

Tax ID no.: A-78267176

Registered office: Avda. de los Reyes, nº 1, Polígono Industrial La Mina, 28770 Colmenar Viejo (Madrid)

Ticker symbol: PHM

Corporate website: [www.pharmamar.com](http://www.pharmamar.com)

**About PharmaMar**

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova and Xylazel. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

**Para más información:****Comunicación:**

Carolina Pola – Communications Director (+34 608 93 36 77)

Paula Fernández de Alarcón – Media Relations Manager (+34 638 79 62 15)

Teléfono: +34 91 846 6000

**Inversores:**

Teléfono: +34 914444500

Para más información, visite nuestra web: [www.pharmamar.com](http://www.pharmamar.com).